828 related articles for article (PubMed ID: 24315973)
1. Distribution of late gadolinium enhancement in end-stage hypertrophic cardiomyopathy and dilated cardiomyopathy: differential diagnosis and prediction of cardiac outcome.
Machii M; Satoh H; Shiraki K; Saotome M; Urushida T; Katoh H; Takehara Y; Sakahara H; Ohtani H; Wakabayashi Y; Ukigai H; Tawarahara K; Hayashi H
Magn Reson Imaging; 2014 Feb; 32(2):118-24. PubMed ID: 24315973
[TBL] [Abstract][Full Text] [Related]
2. Myocardial fibrosis as a key determinant of left ventricular remodeling in idiopathic dilated cardiomyopathy: a contrast-enhanced cardiovascular magnetic study.
Masci PG; Schuurman R; Andrea B; Ripoli A; Coceani M; Chiappino S; Todiere G; Srebot V; Passino C; Aquaro GD; Emdin M; Lombardi M
Circ Cardiovasc Imaging; 2013 Sep; 6(5):790-9. PubMed ID: 23934992
[TBL] [Abstract][Full Text] [Related]
3. [Clinical significance of late gadolinium enhancement on cardiovascular magnetic resonance in patients with hypertrophic cardiomyopathy].
Dumont CA; Monserrat L; Soler R; Rodríguez E; Fernández X; Peteiro J; Bouzas B; Piñón P; Castro-Beiras A
Rev Esp Cardiol; 2007 Jan; 60(1):15-23. PubMed ID: 17288951
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of blood pressure response plus gadolinium enhancement in dilated cardiomyopathy.
Tateishi E; Noguchi T; Goto Y; Morita Y; Ishibashi-Ueda H; Yamada N; Kanzaki H; Nishimura K; Miyamoto Y; Anzai T; Ogawa H; Yasuda S
Heart; 2015 May; 101(10):774-80. PubMed ID: 25761994
[TBL] [Abstract][Full Text] [Related]
5. CMR assessment and clinical outcomes of hypertrophic cardiomyopathy with or without ventricular remodeling in the end-stage phase.
Cheng S; Choe YH; Ota H; Cui C; Yin G; Lu M; Li L; Chen X; Prasad SK; Zhao S
Int J Cardiovasc Imaging; 2018 Apr; 34(4):597-605. PubMed ID: 29071521
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of delayed enhancement magnetic resonance imaging to differentiate dilated phase of hypertrophic cardiomyopathy and dilated cardiomyopathy.
Matoh F; Satoh H; Shiraki K; Saitoh T; Urushida T; Katoh H; Takehara Y; Sakahara H; Hayashi H
J Card Fail; 2007 Jun; 13(5):372-9. PubMed ID: 17602984
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.
Chan RH; Maron BJ; Olivotto I; Pencina MJ; Assenza GE; Haas T; Lesser JR; Gruner C; Crean AM; Rakowski H; Udelson JE; Rowin E; Lombardi M; Cecchi F; Tomberli B; Spirito P; Formisano F; Biagini E; Rapezzi C; De Cecco CN; Autore C; Cook EF; Hong SN; Gibson CM; Manning WJ; Appelbaum E; Maron MS
Circulation; 2014 Aug; 130(6):484-95. PubMed ID: 25092278
[TBL] [Abstract][Full Text] [Related]
8. Myocardial tissue characterization using magnetic resonance noncontrast t1 mapping in hypertrophic and dilated cardiomyopathy.
Dass S; Suttie JJ; Piechnik SK; Ferreira VM; Holloway CJ; Banerjee R; Mahmod M; Cochlin L; Karamitsos TD; Robson MD; Watkins H; Neubauer S
Circ Cardiovasc Imaging; 2012 Nov; 5(6):726-33. PubMed ID: 23071146
[TBL] [Abstract][Full Text] [Related]
9. Late gadolinium enhancement in cardiovascular magnetic resonance in patients with hypertrophic cardiomyopathy complicated by life-threatening ventricular tachyarrhythmia.
Petkow-Dimitrow P; Klimeczek P; Vliegenthart R; Pasowicz M; Miszalski-Jamka T; Oudkerk M; Podolec P; Dubiel JS; Tracz W
Kardiol Pol; 2009 Aug; 67(8A):964-9. PubMed ID: 19784900
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular magnetic resonance characteristics in children with hypertrophic cardiomyopathy.
Chaowu Y; Shihua Z; Jian L; Li L; Wei F
Circ Heart Fail; 2013 Sep; 6(5):1013-20. PubMed ID: 23873474
[TBL] [Abstract][Full Text] [Related]
11. Effects of myocardial fibrosis and ventricular dyssynchrony on response to therapy in new-presentation idiopathic dilated cardiomyopathy: insights from cardiovascular magnetic resonance and echocardiography.
Leong DP; Chakrabarty A; Shipp N; Molaee P; Madsen PL; Joerg L; Sullivan T; Worthley SG; De Pasquale CG; Sanders P; Selvanayagam JB
Eur Heart J; 2012 Mar; 33(5):640-8. PubMed ID: 22048681
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy.
Rubinshtein R; Glockner JF; Ommen SR; Araoz PA; Ackerman MJ; Sorajja P; Bos JM; Tajik AJ; Valeti US; Nishimura RA; Gersh BJ
Circ Heart Fail; 2010 Jan; 3(1):51-8. PubMed ID: 19850699
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of late gadolinium enhancement in patients<20 years of age with hypertrophic cardiomyopathy.
Smith BM; Dorfman AL; Yu S; Russell MW; Agarwal PP; Mahani MG; Lu JC
Am J Cardiol; 2014 Apr; 113(7):1234-9. PubMed ID: 24513464
[TBL] [Abstract][Full Text] [Related]
14. Myocardial fibrosis and quality of life in patients with non-ischemic cardiomyopathy: a cardiovascular magnetic resonance imaging study.
Khan R; Massel D; Stirrat J; Scholl D; Wisenberg G; Thompson T; Drangova M; White JA
Int J Cardiovasc Imaging; 2013 Feb; 29(2):395-404. PubMed ID: 22875171
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of discrepant mid-wall late gadolinium enhancement in patients with nonischemic dilated cardiomyopathy.
Ehara S; Matsumoto K; Kitada R; Nishimura S; Shimada K; Yoshiyama M
Heart Vessels; 2018 Dec; 33(12):1482-1489. PubMed ID: 29804280
[TBL] [Abstract][Full Text] [Related]
16. Intermediate-signal-intensity late gadolinium enhancement predicts ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy.
Appelbaum E; Maron BJ; Adabag S; Hauser TH; Lesser JR; Haas TS; Riley AB; Harrigan CJ; Delling FN; Udelson JE; Gibson CM; Manning WJ; Maron MS
Circ Cardiovasc Imaging; 2012 Jan; 5(1):78-85. PubMed ID: 22135401
[TBL] [Abstract][Full Text] [Related]
17. Cardiac magnetic resonance and galectin-3 level as predictors of prognostic outcomes for non-ischemic cardiomyopathy patients.
Hu DJ; Xu J; Du W; Zhang JX; Zhong M; Zhou YN
Int J Cardiovasc Imaging; 2016 Dec; 32(12):1725-1733. PubMed ID: 27566192
[TBL] [Abstract][Full Text] [Related]
18. Distribution of Hypertrophy and Late Gadolinium Enhancement in Children and Adolescents with Hypertrophic Cardiomyopathy.
Windram JD; Benson LN; Dragelescu A; Yoo SJ; Mertens L; Wong D; Grosse-Wortmann L
Congenit Heart Dis; 2015; 10(6):E258-67. PubMed ID: 26193909
[TBL] [Abstract][Full Text] [Related]
19. Fat deposition in dilated cardiomyopathy assessed by CMR.
Lu M; Zhao S; Jiang S; Yin G; Wang C; Zhang Y; Liu Q; Cheng H; Ma N; Zhao T; Chen X; Huang J; Zou Y; Song L; He Z; An J; Renate J; Xue H; Shah S
JACC Cardiovasc Imaging; 2013 Aug; 6(8):889-98. PubMed ID: 23850250
[TBL] [Abstract][Full Text] [Related]
20. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy.
Klopotowski M; Kukula K; Malek LA; Spiewak M; Polanska-Skrzypczyk M; Jamiolkowski J; Dabrowski M; Baranowski R; Klisiewicz A; Kusmierczyk M; Jasinska A; Jarmus E; Kruk M; Ruzyllo W; Witkowski A; Chojnowska L
J Cardiol; 2016 Jul; 68(1):49-56. PubMed ID: 26363820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
